Navigation Links
Common Chemotherapy Drug Linked to Memory Problems
Date:4/21/2008

'Chemo brain' a routine side effect of treatment with drug 5-fluorouracil, study says

MONDAY, April 21 (HealthDay News) -- Treatment with a single, commonly used chemotherapy drug causes memory problems and other cognitive difficulties, a common and unpleasant side effect called "chemo brain," a new study found.

Up to 50 percent of women with breast cancer reported having cognitive problems a year after chemotherapy treatment ended, according to one previous study.

Now, researchers from the University of Rochester Medical Center in New York and Harvard Medical School say they've discovered how the chemotherapy drug 5-fluorouracil -- or 5-FU -- affects the central nervous system even long after treatment ends. The hope is this discovery will lead to ways to decrease or eliminate the damage so cognitive functioning is preserved.

"What we found is the damage done short-term is much less than the damage that occurs long-term," said Mark Noble, senior author of the study published in the April 22 issue of the Journal of Biology. "After the drug is stopped, the cellular damage gets worse."

For years, experts questioned whether chemo brain was a result of chemotherapy or having cancer itself, said Noble, director of the University of Rochester Stem Cell and Regenerative Medicine Institute. "Could they be depressed? Was it really organic damage?" he said, listing some of the suggested possible causes.

"What our studies do is demonstrate [that] it is the chemo," he said. And, the damage can occur with treatment with the single drug, not only the "cocktails" of drugs often used to treat cancer.

In a previous study, Nobel and his colleagues demonstrated that three common chemotherapy drugs were more toxic to healthy brain cells than to the cancer cells they were meant to treat. These studies were among the first to establish a biological basis for chemo brain. But the research didn't explain why the cognitive ill effects persist in some patients.

For the new study, Noble and his colleagues exposed cell lines in a laboratory and in mice to doses of 5-FU, and then evaluated the drug's effects. The drug is used to treat malignancies of the breast, ovaries, stomach, colon and other sites.

The researchers found that 5-FU damaged specific kinds of cells in the central nervous system -- immature cells known as progenitor cells, which later differentiate into specialized cells.

Also damaged were cells called oligodendrocytes, which help produce myelin, the fatty substance that coats nerve cells and facilitates communication between cells.

"The damage at eight weeks was considerably greater than one day after treatment," Noble said. "Damage at six months was even greater than at six weeks."

The finding "means that there is a real physiological basis for the symptoms of 'chemobrain,'" said Dr. Christina A. Meyers, chief of the department of neuro-oncology at M.D. Anderson Cancer Center, in Houston, who wrote an accompanying comment. "Until we know enough to develop targeted treatments for it, there is still lots to do about it [and better to have it than the alternative]." Among the remedies are relaxation training to focus attention, exercise, cognitive rehabilitation and medicine such as anti-inflammatory agents, she said.

Another cancer expert praised the study.

"This is a very good animal model," said Dr. Patricia Ganz, director of cancer prevention and control at the University of California, Los Angeles Jonsson Cancer Center.

But she added a caveat: "This does not mean that everybody receiving this drug will have damage to their brain," she said. And, she added, this is the effect of just one chemotherapy drug, 5-FU. Today, 5FU is "rarely used in breast cancer treatment," she said.

Noble hopes to focus next on why the damage continues. Eventually, his research may lead to a treatment that can be given to decrease or eliminate the harm to healthy cells, he said.

More information

To learn more about chemo brain, visit American Cancer Society.



SOURCES: Mark Noble, Ph.D., director, University of Rochester Stem Cell and Regenerative Medicine Institute, Rochester, N.Y.; Patricia Ganz, M.D., director, cancer prevention and control research, University of California, Los Angeles, Jonsson Cancer Center; Christina A. Meyers, Ph.D., professor and chief, department of neuro-oncology, M.D. Anderson Cancer Center, Houston; April 21, 2008, Journal of Biology


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. UK junior doctors gaining less experience of common procedures
2. New insights into common knee injuries
3. High and mighty: first common height gene identified by researchers behind obesity gene finding
4. Figure Skater Peggy Fleming, HealthSaver Says: Take Pains For Back Strains, 2nd Most Common Doctor Complaint
5. Exelixis Commences Public Offering of Common Stock
6. Common misdiagnosis: most women believe they have a yeast infection when they dont
7. Business Executives Discuss National Health Care Reform at Conference Sponsored by The Century Foundation, with Support from The Commonwealth Fund, and AARP
8. New Expert Report Dispels Common Myths About Aspartame
9. Common Foot Myths Trip Us Up
10. AHPC Holdings, Inc. Announces Intent to Deregister Common Stock With Securities and Exchange
11. Allergy-Induced Asthma More Common in Affluent Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... 2017 , ... Wells Pharmacy Network offers physicians WellsPx3, a ... non-controlled substances plus the ability to manage orders on their desktop or mobile ... electronic prescriptions, according to the Office of the National Coordinator of Health IT, ...
(Date:2/17/2017)... Seattle, WA (PRWEB) , ... February 17, 2017 ... ... health management organizations, has been named a finalist in the 8th Annual DecisionHealth ... impacting America's healthcare delivery system. Qualis Health’s work is recognized across multiple award ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... Chief Executive Officer, George Rogers, was named to Staffing Industry Analysts' 2017 "Staffing ... 100 honors those who have made notable contributions to the staffing industry over ...
(Date:2/17/2017)... Plantation, FL (PRWEB) , ... February 17, 2017 ... ... protection services and financial planning assistance to families and business owners in the ... the LifeNet 4 Families organization. , For more than 30 years, LifeNet ...
(Date:2/16/2017)... (PRWEB) , ... February 16, 2017 , ... ... nursing professionalism, teamwork and superiority in patient care, NWH has achieved Magnet® ... on Magnet on Tuesday, January 31, 2017. The American Nurses Credentialing Center’s Magnet ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... YORK , Feb. 17, 2017   Risperdal ... side effects allegedly associated with use of the atypical ... Philadelphia Court of Common Pleas, where ... mass tort program. According to a notice posted on ... to convene a meeting on March 9, 2017 at ...
(Date:2/17/2017)... 17, 2017 On Thursday, February ... edged lower at the closing bell, while the Dow ... 20,000 benchmark. Moreover, five out of nine sectors ended ... yesterday,s market sentiment, Stock-Callers.com assessed the following Medical Appliances ... (NYSE: SNN ), ABIOMED Inc. (NASDAQ: ...
(Date:2/16/2017)... Inc. (NYSE: DVA ) today announced results for ... Net income attributable to DaVita Inc. for the quarter ... $0.80 per share and $880 million, or $4.29 per share, ... Inc. for the quarter and year ended December 31, 2016, ... $0.98 per share, and $789 million, or $3.85 per share, ...
Breaking Medicine Technology: